

# Leqembi™ [Lecanemab-irmb]

Provider Order Form rev. 8/10/2023

## PATIENT INFORMATION

Referral Status (check one): ☐ New Referral ☐ Updated Order ☐ Order Renewal

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_

NKDA ☐ Allergies: \_\_\_\_\_ Weight \_\_\_\_\_ Please specify: ☐ lbs ☐ kg Height: \_\_\_\_\_

Patient Status (check one): ☐ New to Therapy ☐ Continuing Therapy | Last Treatment Date: \_\_\_\_\_ Next Due Date: \_\_\_\_\_

ICD-10 code (required): \_\_\_\_\_ ICD-10 description: \_\_\_\_\_

**REQUIRED: Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.**

## PRESCRIPTION

- ☐ Provide nursing care per AdaptIV Infusion Nursing Procedures, including reaction management and post-procedure observation  
☐ Medicare Registry # \_\_\_\_\_

### DIAGNOSIS:

- ☐ G30.0 Alzheimer's Disease, Early Onset  
☐ G30.1 Alzheimer's Disease, Late Onset  
☐ G30.8 Other Alzheimer's disease  
☐ G30.9 Alzheimer's disease, unspecified  
☐ G31.84 Mild Cognitive Impairment, So Stated

### G30.X codes require secondary F02.8X code BELOW:

- ☐ F02.80 Dementia without behavioral disturbance  
☐ F02.81 Dementia with behavioral disturbance

### PRESCRIBER MUST INDICATE THE FOLLOWING REQUIREMENTS HAVE BEEN MET (PLEASE PROVIDE DOCUMENTATION):

- ☐ Beta Amyloid Pathology Confirmed Via:  
☐ Amyloid PET Scan Date: \_\_\_\_\_  
**OR**  
☐ CSF Analysis Date: \_\_\_\_\_ Result: \_\_\_\_\_  
☐ Cognitive Assessment Used:  
Date: \_\_\_\_\_ Result: \_\_\_\_\_  
☐ ApoE E4 Genetic Test: Date: \_\_\_\_\_  
Result: ☐ Homozygote ☐ Heterozygote ☐ Noncarrier

### PRE-INFUSION:

- ☐ Confirm baseline MRI results prior to initiation of treatment.  
☐ Confirm MRI completed and reviewed by prescriber prior to the 5th, 7th, and 14th treatment.  
☐ Measure and record weight prior to each treatment to determine dose.  
☐ Hold infusion and notify provider if patient reports:  
• Headache • Vision changes  
• Dizziness • New or worsening confusion  
• Nausea

### MEDICATION:

- ☐ Administer LEQEMBI 10 mg/kg intravenously over at least 60 minutes.  
☐ Dilute required volume of lecanemab-irmb in 250 ml 0.9% sodium chloride and infuse using a terminal low-protein binding 0.2-micron in-line filter.  
☐ If infusion-related reaction occurs, stop infusion and treat per orders/protocol as clinically indicated.

### TREATMENT FREQUENCY:

- ☐ 10mg/kg IV every 2 weeks  
☐ 10mg/kg IV every 4 weeks (after 18 months of treatment only)

### POST-INFUSION:

- ☐ Educate patient/care partner to report headache, dizziness, nausea, vision changes, or new/worsening confusion.  
☐ Fax treatment notes to provider at number below.

## SPECIAL INSTRUCTIONS

## PROVIDER INFORMATION

Referral Coordinator Name: \_\_\_\_\_ Referral Coordinator Email: \_\_\_\_\_

Ordering Provider: \_\_\_\_\_ Provider NPI: \_\_\_\_\_

Referring Practice Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

Practice Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip Code: \_\_\_\_\_

Provider Name (Print)

Provider Signature

Date

**REQUIRED: PLEASE INCLUDE ALL REQUIRED LABS AND A COPY OF PATIENT'S INSURANCE CARD – FRONT AND BACK**